Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Emerging small molecule strategies target cancer stem cells through ferroptosis and metabostemness

Farah H., Abdulsahib WK., Ismael SH., Roopashree R., Ray S., Nandhini SU.

Narrative Review on Systemic / IV, published in Discov Oncol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Discov Oncol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41390898
PMCID
PMC12819955
DOI
10.1007/s12672-025-04259-4

Abstract (original English)

Cancer remains a formidable global health challenge, with therapeutic resistance and disease relapse frequently attributed to the persistence of a resilient subpopulation of cells known as cancer stem cells (CSCs). These cells, characterized by self-renewal capacity, continuous proliferation, and multi-lineage differentiation potential, drive tumorigenesis, metastasis, and evade conventional therapies. Traditional cancer treatments often fail to eradicate CSCs, leading to their enrichment post-therapy and subsequent tumor recurrence. This comprehensive review explores two innovative and interconnected therapeutic paradigms for targeting CSCs: ferroptosis and metabostemness. Ferroptosis, an iron-dependent form of regulated cell death distinct from apoptosis, offers a promising avenue to overcome apoptosis resistance prevalent in many cancers, including CSCs, by inducing lethal lipid peroxidation. Concurrently, “metabostemness” describes the unique metabolic reprogramming of CSCs, encompassing alterations in glucose, lipid, and amino acid metabolism, which are critical for maintaining their stemness, survival, and resistance to treatment. This review synthesizes the current understanding of the molecular mechanisms underlying ferroptosis and metabostemness in CSCs, highlighting emerging small-molecule strategies designed to exploit these vulnerabilities. The discussion includes d

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research